Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion.

Sylvia Nghiem-BuffetAgnès Glacet-BernardManar Addou-RegnardEric H SouiedSalomon Y CohenAudrey Giocanti-Auregan

Published in: Journal of ophthalmology (2018)

In case of insufficient response or frequent recurrences of ME due to CRVO in patients treated with ranibizumab on a TAE basis, switching to aflibercept could allow extending treatment intervals, which could reduce the injection burden for these patients.

Keyphrases

age related macular degeneration
diabetic retinopathy
optical coherence tomography
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
ultrasound guided
prognostic factors
risk factors